News & Events2019-09-26T11:49:21-04:00

News & Events

Observations, opinions, and opportunities presented by our experts


Precision’s Baumgardner Warns HIV Advances Could Be Negatively Impacted by Changes to Medicare Part D Rule

In Spotlight on Market Access, Precision senior research economist James Baumgardner provides his perspective on HHS’ proposed changes to Medicare Part D loosening government restrictions on 4 protected drug classes, including those to treat HIV. Baumgardner cautions the rule changes “directly imperils those with HIV who have Medicare as their source of health coverage,” and urges greater adoption of HIV prevention efforts, including the use of new PrEP treatments that can greatly reduce the risk of acquiring HIV.

The complete article can be viewed below: 


Load More Posts

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

By continuing to use our website, you agree to our use of cookies to help us give you the best experience, analyze your site usage, and assist in our marketing efforts.
For more information, or to learn how to change your cookies preferences, please click here.